Antagonism of Bcl-X(L) is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells

BACKGROUND: BH3 mimetics are a class of drugs that antagonize the Bcl-2 family of apoptosis inhibitors. We have previously shown that these compounds can potentiate the activity of carboplatin against several ovarian cancer cell lines. However, recent clinical studies have highlighted that BH3 mimet...

Descripción completa

Detalles Bibliográficos
Autores principales: Abed, Mohammed Najim, Abdullah, Marwan Ibrahim, Richardson, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832520/
https://www.ncbi.nlm.nih.gov/pubmed/27080533
http://dx.doi.org/10.1186/s13048-016-0234-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832520/
https://www.ncbi.nlm.nih.gov/pubmed/27080533
http://dx.doi.org/10.1186/s13048-016-0234-y

Ejemplares similares